LASSARAB+ aPHAD-SEat 700rU

Phase 1Biologic

WWilbur Chen, MD, MS

LASSARAB+ aPHAD-SEat 700rU is one of 5 biologic programs targeting Lassa fever. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lassa FeverActive, not recruiting

Lassa FeverPhase 1

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Lassa Fever

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

2 2

Virazole

CConrado Roberto Hoffmann Filho

Phase 2

4 3

Avigan

AAppili Therapeutics Inc.

Phase 2

2 4

ARN-75039

AArisan Therapeutics, Inc.

Phase 2

1 5

LASSARAB+ aPHAD-SEat 700rU

WWilbur Chen, MD, MS

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lassa fever1 trial

DMID 23-0015; Lassa Fever CVD 1000

Active, not recruiting·WWilbur Chen, MD, MS·Phase 1·NCT06546709·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LASSARAB+ aPHAD-SEat 700rU. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LASSARAB+ aPHAD-SEat 700rU compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LASSARAB+ aPHAD-SEat 700rU. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Wilbur Chen, MD, MS company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: WWilbur Chen, MD, MS

LASSARAB+ aPHAD-SEat 700rU

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lassa fever1 trial

References

Drug Info

Quick Facts

Related News